A Commercial-Stage Moderna Debuts At J.P. Morgan
Executive Summary
Moderna has received $2.8bn for advance purchase agreements for its COVID-19 vaccine, with much more to follow. Management outlined some initial financial updates for investors.
You may also be interested in...
Speculation Over Moderna Vaccine Deal With Tata, Wockhardt
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.
J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.